Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

ClinicalTrials.gov ID: NCT07594119

Public ClinicalTrials.gov record NCT07594119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Study identification

NCT ID: NCT07594119
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Rapport Therapeutics Inc.; Industry
Enrollment: 312 participants

Conditions and interventions

Conditions

Interventions

RAP-219 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2026
Primary completion: Jun 30, 2029
Completion: Aug 31, 2029
Last update posted: Sep 1, 2026

2026 – 2029

United States locations

U.S. sites: 11
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
Clinic for Neurology	Huntsville	Alabama	35801	Recruiting
Pillar Clinical Research	Bentonville	Arkansas	72712	Recruiting
Colorado Springs Neurological Associates	Colorado Springs	Colorado	80919	Recruiting
K2 Medical Research	Maitland	Florida	32751	Recruiting
Serenity Research Center, LLC	Miami	Florida	33176	Recruiting
Re:Cognition Health-Chicago	Chicago	Illinois	60611	Recruiting
Lenox Hill Hospital	New York	New York	10075	Recruiting
Velocity Clinical Research	Raleigh	North Carolina	27607	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37179	Recruiting
Baylor College of Medicine	Houston	Texas	77030	Recruiting
University of Texas Health Science Center in Houston	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07594119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07594119 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →